Non-CNS Penetrant Products Sample Clauses

Non-CNS Penetrant Products. Lilly shall make each of the following milestone payments to Rigel for each Non-CNS Penetrant Product to achieve the corresponding milestone event for the applicable Indication for which such milestone event has been met.
Sample 1
AutoNDA by SimpleDocs
Non-CNS Penetrant Products. Lilly shall make each of the milestone payments indicated below to Rigel, on a Non-CNS Penetrant Product-by-Non-CNS Penetrant Product basis, when aggregate, cumulative Net Sales of the applicable Non-CNS Penetrant Product across all Indications in the Territory first reach the specified dollar values in any Calendar Year. Each such milestone payment shall be non-refundable and non-creditable against any other payment due under this Agreement. Aggregate Net Sales in the Territory for a Non-CNS Penetrant Product in a Calendar Year Milestone Payment $[*] $[*] $[*] $[*]
Sample 1
Non-CNS Penetrant Products. On a Non-CNS Penetrant Product-by-Non-CNS Penetrant Product basis, during the Royalty Term, Lilly shall pay to Rigel non-refundable, non-creditable royalties on Net Sales of each Non-CNS Penetrant Product in the Territory as calculated by multiplying the applicable amount of incremental Net Sales of such Non-CNS Penetrant Product in the Territory in the applicable Calendar Year by the applicable royalty rate set forth: (i) in the case of the R552 Product or any other Non-CNS Penetrant Product for which Rigel has exercised its Cost Sharing Option, (A) in column A of the following table if Rigel has not provided a Stage 1 Opt-Out Notice or Stage 2 Opt-Out Notice; (B) in column B of the following table if Rigel has provided a Stage 1 Opt-Out Notice; or (C) in column C of the following table if Rigel has provided a Stage 2 Opt-Out Notice or (ii) in the case of any Non-CNS Penetrant Product other the R552 Product for which Rigel has not exercised its Cost Sharing Option, in column B of the following table: ​ ​
Sample 1

Related to Non-CNS Penetrant Products

  • New Products You agree to comply with NASD Notice to Members 5-26 recommending best practices for reviewing new products.

  • Combination Products If a LICENSED PRODUCT is sold to any third party in combination with other products, devices, components or materials that are capable of being sold separately and are not subject to royalties hereunder (“OTHER PRODUCTS,” with the combination of products being referred to as “COMBINATION PRODUCTS” and the Other Product and Licensed Product in such Combination Product being referred to as the “COMPONENTS”), the NET SALES of such LICENSED PRODUCT included in such COMBINATION PRODUCT shall be calculated by multiplying the NET SALES of the COMBINATION PRODUCT by the fraction A/(A+B), where A is the average NET SALES price of such LICENSED PRODUCT in the relevant country, as sold separately, and B is the total average NET SALES price of all OTHER PRODUCTS in the COMBINATION PRODUCT in the relevant country, as sold separately. If, in any country, any COMPONENT is not sold separately, NET SALES for royalty determination shall be determined by the formula [C / (C+D)], where C is the aggregate average fully absorbed cost of the Licensed Product components during the prior Royalty Period and D is the aggregate average fully absorbed cost of the other essential functional components during the prior Royalty Period, with such costs being determined in accordance with generally accepted accounting principles. To the extent that any SUBLICENSE INCOME relates to a COMBINATION PRODUCT or is otherwise calculated based on the value of one or more licenses or intellectual property rights held by the COMPANY, an AFFILIATE or SUBLICENSEE, COMPANY shall determine in good faith and report to THE PARTIES the share of such payments reasonably attributable to COMPANY’s or such AFFILIATE’s sublicense of the rights granted hereunder, based upon their relative importance and proprietary protection, which portion shall be the SUBLICENSE INCOME. THE PARTIES shall have the right to dispute such sharing determination in accordance with the dispute provisions of the AGREEMENT.

  • Licensed Products Lessee will obtain no title to Licensed Products which will at all times remain the property of the owner of the Licensed Products. A license from the owner may be required and it is Lessee's responsibility to obtain any required license before the use of the Licensed Products. Lessee agrees to treat the Licensed Products as confidential information of the owner, to observe all copyright restrictions, and not to reproduce or sell the Licensed Products.

  • Manufacturing Rights Manufacturing Rights will be governed by Attachment 6.

  • Supply of Products TheraSense shall be responsible for the ------------------ manufacture of FreeStyle Products for sale to Nipro.

  • Net Sales The term “

  • Competing Products The provisions of Section 21 are set forth on attached Exhibit H and are incorporated in this Section 21 by this reference.

  • Combination Product The term “

  • Raw Materials Lonza shall procure all required Raw Materials as well as consumables other than those Raw Materials that are Customer Materials. Customer shall be responsible for payment for all consumables and Raw Materials ordered or irrevocably committed to be procured by Lonza hereunder. Upon cancellation of any Batch or termination of the Agreement, all unused Raw Materials shall be paid for by Customer within [***] days of invoice and at Customer’s option will either be (a) held by Lonza for future use for the production of Product, (b) delivered to Customer, or (c) disposed of by Lonza.

  • Products 1.1. The information (including but not limited to the quantity, rated hashrate, unit price (“Unit Price”), total price for one item (“Total Price (One Item)”), total price for all the items (“Total Purchase Price”) of Products to be purchased by Party B from Party A is as follows (“Products”):

Time is Money Join Law Insider Premium to draft better contracts faster.